{"id":12568,"date":"2008-10-06T18:30:00","date_gmt":"2008-10-06T16:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/pharmakronos-quotidiano-di-informazione-farmaceutica-del-06102008\/"},"modified":"2008-10-06T18:30:00","modified_gmt":"2008-10-06T16:30:00","slug":"pharmakronos-quotidiano-di-informazione-farmaceutica-del-06102008","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/pharmakronos-quotidiano-di-informazione-farmaceutica-del-06102008\/","title":{"rendered":"PHARMAKRONOS, PHARMACEUTICAL INFORMATION NEWSPAPER OF 06\/10\/2008"},"content":{"rendered":"<p><strong><font size=\"3\">oggi su Pharmakronos puoi trovare: (<a href=\"http:\/\/streamer.adnkronos.com\/Salute\/Newsletter\/data\/Pk154okk.pdf\" target=\"_blank\" rel=\"noopener\">click here<\/a>)<\/font><\/strong><\/p>\n<p><strong><font size=\"3\">&raquo; Anticancro verso 42 mld dollari <br \/> &raquo; Europa a pi&ugrave; velocit&agrave; su offerta vaccini <br \/> &raquo; Mylan punta al generico del futuro <br \/> &raquo; Gsk patteggia class action negli Usa <br \/> &raquo; Merck&amp;Co interrompe test su taranabant <br \/> &raquo; Ceo dei paesi emergenti? Geniali ma poco concreti <br \/> &raquo; Francia, Sanofi-Aventis taglia 927 posti <\/font><\/strong><\/p>\n<p align=\"center\"><font size=\"5\"><strong>Pharma<em>Kronos<\/em><\/strong><\/font><font size=\"5\">&nbsp;<\/font><font size=\"1\">&nbsp;<\/font><\/p>\n<p align=\"center\"><font size=\"1\"><strong>Pharmakronos \u2013 daily pharmaceutical information.&nbsp;<\/strong><\/font><strong><font size=\"1\">Free supplement to today&#039;s edition of <\/font><a href=\"http:\/\/www.adnkronos.com\/Salute\/hp\/\" target=\"_blank\" rel=\"noopener\"><font size=\"1\">Adnkronos Salute<\/font><\/a><font size=\"1\">.&nbsp;<\/font><\/strong><\/p>\n<p align=\"center\"><strong><font size=\"1\">Director \u2013 Giuseppe Marra.&nbsp;<\/font><\/strong><strong><font size=\"1\">Responsible director \u2013 Francesco Maria Avitto.&nbsp;<\/font><\/strong><\/p>\n<p align=\"center\"><strong><font size=\"1\">Edited by: Federica Iannetti and Barbara Di Chiara .<\/font><\/strong><\/p>\n<p>as<\/p>","protected":false},"excerpt":{"rendered":"<p>oggi su Pharmakronos puoi trovare: (click qui) &raquo; Anticancro verso 42 mld dollari &raquo; Europa a pi&ugrave; velocit&agrave; su offerta vaccini &raquo; Mylan punta al generico del futuro &raquo; Gsk patteggia class action negli Usa &raquo; Merck&amp;Co interrompe test su taranabant &raquo; Ceo dei paesi emergenti? Geniali ma poco concreti &raquo; Francia, Sanofi-Aventis taglia 927 &hellip;<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-12568","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/12568","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=12568"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/12568\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=12568"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=12568"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=12568"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}